Pulmonary Interstitial Fibrosis(Lung Disease)

Vertex Pharmaceuticals Inc significantly improved lung function in patients with cystic fibrosis, sending the company's shares up 18 percent to a four-year high. Vertex said it will file for U.S. approval of the drug, known as VX-770, in the second half of this year. Cystic fibrosis is an inherited disease that affects the lungs and digestive system. It affects about 30,000 people in the United States, according to the Cystic Fibrosis Foundation. Results of a late-stage trial showed the drug improved lung function more than 10 percent, far greater than Wall Street had expected. "These are potentially game-changing data in cystic fibrosis," Mark Schoenebaum, an analyst at ISI Group, said in a research note. "VX-770 is the first drug to show good data in a Phase III that actually modifies the disease by binding to a defective protein and fixing it."

I own stock in vertex so above is from C. Schwab's Email to me today.
 
"... InterMune today announced that the European Commission (EC) has granted marketing authorization for Esbriet(R) (pirfenidone). Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. ..."

More at: http://pharmalive.com/news/index.cfm?articleid=765729&categoryid=47
Billy T said:
{post 66}.... "From BioWorld Today (May 5, 2010) but see where I copied from at first link.

InterMune Inc. failed to win FDA approval of Esbriet (pirfenidone) as a treatment for a fatal lung disease, known as idiopathic pulmonary fibrosis (IPF), despite the strong backing of an agency panel of experts. ... CEO Dan Welch said it currently is unclear whether his firm would need to conduct an entirely new study or if it could submit data from a Phase III study conducted by Osaka, Japan-based Shionogi & Co. Ltd., which holds the rights to pirfenidone in Japan, where it is sold as Pirespa. ...
Click to expand...
Japan & EU have it on the market but not the US:
 
Last edited by a moderator:
"This first launch of Esbriet is an important occasion for patients in Germany and for InterMune," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "For the first time, German patients with IPF will have access to a medicine proven to reduce the decline in lung function, offering a treatment where none existed previously. Our team in Germany is well staffed and trained, and fully committed to making Esbriet available to all appropriate patients as rapidly as possible and our entire organization is actively preparing to launch Esbriet throughout Europe beginning in the first half of 2012." ..." From: http://pharmalive.com/news/index.cfm?articleid=802338&categoryid=69

I errored in post 85. Only Japan had it on the market in early 2011, but Germany does now. How many Americans must suffer before this, the only aid, is available in the US? What is really needed is a cure, FDA's excessive foot dragging is making that years way as the drug companies want to at least make small profit - years of delay getting a well demonstrated, safe, drug on market makes them hesitate to invest in the needed research.
 
Last edited by a moderator:
Finally soon help is at least near the US:
http://pharmalive.com/news/index.cfm?articleID=860013&categoryid=9&newsletter=1 said:
".. Professor and Vice-Chair of Medicine, University of Toronto. "I am very pleased to finally have a treatment option with proven benefit for patients with this challenging disease."

Pirfenidone is the first and only medicine approved anywhere in the world for the treatment of IPF. In addition to Canada, pirfenidone is approved in 29 European countries under the InterMune trade name Esbriet and in Japan and South Korea where it is marketed by Shionogi & Co. Ltd under the trade name Pirespa®. Under different trade names, pirfenidone is also approved for the treatment of IPF in China, India, and Argentina. InterMune is conducting an additional Phase 3 study, ASCEND, to support the regulatory registration of Esbriet for the treatment of IPF in the United States.

"With the approval of Esbriet by Health Canada we are very pleased to have made another big step toward our objective to bring Esbriet to as many IPF patients as possible – and as soon as possible," said Daniel Welch, Chairman, Chief Executive Officer and President of InterMune.

While Health Canada has now approved Esbriet for the treatment of mild to moderate IPF in adult patients, it is not yet available for sale in Canada. InterMune expects that Esbriet will be available on January 1, 2013.
Click to expand...
How many have died in US waiting?
 
Regarding present health recovery from IPF

*** Since 10-05-12, 08:12 PM, I don't notice any posts in this thread "Thread: Pulmonary Interstitial Fibrosis(Lung Disease)"
*** Due to this, many of us are unable to get updates on various IPF treatments suggested on this thread.
*** Please someone let me know.... is this post closed or Moved to other location?

Hello Mr. Prakash Lakhapate,

Hope you are doing well. All your posts indicate that you did a deep-research and have put rest-less efforts to treat your wife recover from IPF.

We wish for her overall good health.

As, from last few months you didn't post anything on her health's improvement, would be great if you post some information about her present health conditions.

That would be a great help of many of us who contacted you & followed your directions and medications to treat IPF of our loved-ones.

That will also keep our moral high.

Thanks!

Regards
 
Last edited:
You must log in or register to reply here.
Back
Top